Literature DB >> 29332209

The rapid diagnosis of viral respiratory tract infections and its impact on antimicrobial stewardship programs.

Şiran Keske1, Önder Ergönül2,3, Faik Tutucu4, Doruk Karaaslan4, Erhan Palaoğlu5, Füsun Can6.   

Abstract

We aimed to describe the potential benefit of new rapid molecular respiratory tests (MRT) in decreasing inappropriate antibiotic use among the inpatients presenting with influenza-like illness (ILI). We included patients from inpatient and outpatient departments who had ILI and performed MRT between 1 January 2015 and 31 December 2016 in a 265-bed private hospital in Istanbul. At the end of 2015, we implemented antimicrobial stewardship including systematic use of MRT. Then, we compared our observations between the year 2015 and the year 2016. We designed the study according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) tool. A U.S. Food and Drug Administration (FDA)-cleared multiplexed polymerase chain reaction (PCR) system (BioFire FilmArray, Idaho Technology, Salt Lake City, UT) which detects 17 viruses and three bacteria was used for diagnosis. In total, 1317 patients were included; 630 (48%) were inpatients and 569 (43%) were older than 16 years of age. At least one virus was detected in 747 (57%) patients. Rhinovirus/enterovirus, influenza virus, and adenovirus were the most commonly detected. Among hospitalized patients, in children, a significant decrease in antibiotic use (44.5% in 2015 and 28.8% in 2016, p = 0.009) was observed, but in adults, the decrease was not statistically significant (72% in 2015 and 63% in 2016, p = 0.36). The duration of antibiotic use after the detection of virus was significantly decreased in both children and adults (p < 0.001 and p = 0.007, respectively). By using MRT, inappropriate antibiotic use and, also, duration of inappropriate antibiotic use after the detection of virus was significantly decreased. It is time to increase the awareness about the viral etiology in respiratory tract infections (RTIs) and implement MRT in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29332209      PMCID: PMC7087990          DOI: 10.1007/s10096-017-3174-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


Introduction

Respiratory tract infections (RTIs) are the most common reasons for admission to healthcare facilities and one of the leading causes of hospitalization [1, 2]. The viral pathogens in the etiology of RTIs became more detectable along with the improvement in molecular diagnostic methods in recent years. In adults, influenza virus, rhinovirus, adenovirus, respiratory syncytial virus (RSV), human coronavirus, and parainfluenza virus cause infections with considerable morbidity and mortality [1, 3], and in infants, RSV is the most common reason for RTIs among hospitalized patients [4]. The antibiotic prescription rate was reported to be more than 60% despite the high proportion of viral etiology [5-8]. Unnecessary antibiotic administration in viral infections and antimicrobial resistance prompted the implementation of antimicrobial stewardship (AMS) programs. The “Implementing an antibiotic stewardship program” guideline by the Infectious Diseases Society of America (IDSA) suggested rapid viral testing for respiratory pathogens to decrease inappropriate antibiotic use [9]. In this study, we aimed to describe the viral etiology in influenza-like illness (ILI) in children and adults and to show the benefit of new rapid molecular respiratory tests (MRT) in decreasing inappropriate antibiotic use.

Methods

Study population and design

We designed the study according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) tool [10]. We included consequent patients from inpatient and outpatient departments, who had moderate to severe ILI, and, therefore, needed further diagnostic evaluation between 1 January 2015 and 31 December 2016 in a 265-bed private hospital in Istanbul. Only the patients whom MRT was implemented for diagnosis were included in this study. MRT was introduced in our hospital in 2013, and the demand for MRT increased over the years. At the end of 2015, we enhanced our training on antimicrobial stewardship (AMS). The intervention consists of training physicians to increase awareness about MRT, highlighting antimicrobial resistance because of unnecessary antibiotic consumption at ad hoc meetings in each related department. Then, we compared our observations between the year 2015 and the year 2016. This was a retrospective study performed by reviewing the patient charts. Clinical features of the patients, demographic characteristics, chronic diseases including malignant disorders, diabetes mellitus, chronic kidney and liver diseases, and detailed information about antibiotic and antiviral drugs during hospitalization were collected by the chart review. Complete blood count, C-reactive protein, and liver and kidney function tests were studied among all patients. Bacterial cultures (throat, sputum, blood, and urine) were obtained, and procalcitonin (PCT) was studied in all patients with suspicion of bacterial infection and/or in critical patients. Chest X-ray and lung computed tomography was done if lower respiratory tract infection (LRTI) was suspected.

Definitions

ILI was defined according to the World Health Organization (WHO) and explained as an acute respiratory infection with fever of ≥ 38 °C and cough and with onset within the last 10 days [11]. Inappropriate antibiotic use was defined as antibiotic use despite detection of virus without documented and/or suspicious bacterial infection. Antibiotic use duration was calculated as the duration of antibiotic use after the detection of virus in patients with inappropriate antibiotic use.

Diagnosis

For molecular detection and identification of respiratory viral pathogens, a U.S. Food and Drug Administration (FDA)-cleared multiplexed respiratory polymerase chain reaction (PCR) system (MRT), BioFire FilmArray (Idaho Technology, Salt Lake City, UT) which detects 17 viral respiratory pathogens (adenovirus, coronavirus HKU1, coronavirus NL63, coronavirus 229E, coronavirus OC43, hMPV, rhinovirus/enterovirus, influenza A, influenza A/H1, influenza A/H1-2009, influenza A/H3, influenza B, parainfluenza 1, parainfluenza 2, parainfluenza 3, parainfluenza 4, and RSV) and three bacteria (Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae) was used according to the manufacturer’s instructions. MRT yielded results within a few hours and the results were immediately reported to the physician of the patients by laboratory staff.

Data analysis

In the statistical analysis, the t-test for continuous variables and the chi-square test for comparison of categorical variables were used. In the analysis, STATA 11 (StataCorp, College Station, TX) was used and a p-value < 0.05 was set as being significant. The Institutional Review Board of Koç University approved the study (2015.172.IRB3.087).

Results

In total, 1317 patients whom MRT was implemented were included; 630 (48%) were inpatients and 569 (43%) were older than 16 years of age. At least one virus was detected in 747 (57%) patients and 359 (48%) of them were inpatients (Fig. 1). Among the patients who have viral pathogens in etiology, 211 (28.2%) were adult, and influenza A (52 of 211) (25%), rhinovirus/enterovirus (49 of 211) (23%), and influenza B (33 of 211) (16%) were the most commonly detected viruses. Among children, rhinovirus/enterovirus (182 of 536) (34%), adenovirus (92 of 536) (17%), influenza A (66 of 536) (12%), RSV (63 of 536) (12%), and influenza B (53 of 536) (10%) were the most commonly detected viruses (Fig. 2). In 71 patients out of 747 (9.5%), multiple viral pathogens were detected.
Fig. 1

Study population. ILI: influenza-like illness; LRTI: lower respiratory tract infection

Fig. 2

The most commonly detected viruses among all patients in whom at least one virus was detected. RSV: respiratory syncytial virus; hMPV: human metapneumovirus

Study population. ILI: influenza-like illness; LRTI: lower respiratory tract infection The most commonly detected viruses among all patients in whom at least one virus was detected. RSV: respiratory syncytial virus; hMPV: human metapneumovirus The overall rate of LRTIs was 57% among inpatients. Among inpatients infected with RSV, the rate of LRTI was 91% in adults and 70% in children. Similarly, in hMPV infections, the rate of LRTI was 73% in adults and 60% in children (Table 1).
Table 1

Clinical and laboratory findings in respiratory system infections caused by different viruses among adult and child inpatients

AdultChildren
No. (%)Mean age (years)LRTI (%)FatalNo. (%)Mean age (years)LRTI (%)Fatal
Rhinovirus/enterovirus20 (20)62.05 (SD = 22.45)11 (55%)079 (31)4.6 (SD = 3.97)29 (37%)0
Adenovirus3 (3)37.7 (SD = 10.6)2 (67%)057 (22)4.09 (SD = 1.71)9 (16%)0
Influenza A32 (32)52.9 (SD = 19.9)17 (53%)132 (14)4.84 (SD = 3.48)5 (16%)0
Influenza B9 (9)49.7 (SD = 15.7)2 (22%)016 (6)5.25 (SD = 3.3)1 (6%)0
RSV11 (11)75.2 (SD = 12.2)10 (91%)033 (13)2.24 (SD = 2.48)23 (70%)0
Coronavirus11 (11)69.9 (SD = 16.1)5 (45%)117 (7)3.35 (SD = 1.87)3 (18%)0
hMPV11 (11)59.9 (SD = 15.8)8 (73%)025 (10)3.16 (SD = 2.54)15 (60%)0
Parainfluenza9 (9)69.4 (SD = 12.8)6 (67%)017 (7)2.35 (SD = 2.52)6 (35%)0
Total101 (100)60.4 (SD = 19.4)57 (57%)2258 (100)3.9 (SD = 3.15)82 (32%)0

RSV: Respiratory syncytial virus; hMPV: human metapneumovirus; LRTI: lower respiratory tract infection

Clinical and laboratory findings in respiratory system infections caused by different viruses among adult and child inpatients RSV: Respiratory syncytial virus; hMPV: human metapneumovirus; LRTI: lower respiratory tract infection In total, among hospitalized patients, antibiotics were continued inappropriately in 45% (160/359) of all inpatients, despite detection of the virus, but there was a reduction in 2016 when compared with 2015 [51.3% (81/158) in 2015 and 39.3% (79/201) in 2016, p = 0.024] (Table 2). In children, the antibiotic continuation rate was 44.5% in 2015 and decreased to 28.8% in 2016 (p = 0.009); in adults, there was a decrease towards 2016 but this was not significant (Table 2). The mean duration of inappropriate antibiotic use after the detection of virus decreased in both adults and children in 2016 when compared with 2015. The most commonly inappropriately used antibiotics were third-generation cephalosporins, quinolones, and second-generation cephalosporins.
Table 2

Antibiotic continuation details of inpatients with positive molecular respiratory tests (MRT)

Childrenp-ValueAdultsp-Value
Before intervention (year 2015)After intervention (year 2016)Before intervention (year 2015)After intervention (year 2016)
Inappropriate antibiotic use (%)53/119 (44.5)40/139 (28.8)0.00928/39 (72)39/62 (63)0.36
Mean duration of inappropriate antibiotic use (days)6.5 (SD 3.1)4.6 (SD 2.0)< 0.0019.7 (SD 7.3)6.2 (SD 3.7)0.007
Antibiotic continuation details of inpatients with positive molecular respiratory tests (MRT)

Discussion

In our study, rhinovirus/enterovirus, influenza, and adenovirus were the most commonly detected viruses in the etiology of ILI. In a recent study by Jain et al. [3], a population-based surveillance for community-acquired pneumonia among adults aged 18 years and older was conducted. Human rhinovirus, influenza A and B virus, and hMPV were the most commonly detected viruses in etiology. Influenza virus and rhinovirus were reported to be the most commonly detected viruses in both adults and children in Turkey [12]. Among inpatients older than 16 years of age, 57% had LRTI, and influenza A, rhinovirus, RSV, and hMPV were the most common agents. Among children, 32% had LRTI, and rhinovirus, RSV, and hMPV were the most common agents (Fig. 2; Table 1). Any effort targeted to reduce the unnecessary use of antibiotics in viral pneumonia could be useful in this era of antibiotic resistance. Because of the high rate of inappropriate antibiotic prescription despite the availability of MRT, we decided to improve training sessions about the diagnosis and management of respiratory system infections at the end of 2015. Then, we performed an observational comparison between the practice in 2015 and 2016. There was a decrease in antibiotic use towards 2016 among all inpatients. However when analyzed separately, a significant reduction in children but not in adults was detected (Table 2). The significant reduction of antibiotic use in children but not in adults could be explained by differences in physicians’ experience in MRT. Despite the fact that there was a reduction in antibiotic use in children after the detection of virus, antibiotic prescription rates were still high. In a recent study, the impact of MRT on antibiotic use was investigated and it was seen that antibiotics were still continued in about 75% of the patients, despite the detection of virus. This finding was explained by being a new test [13]. In another study, Afzal et al. [14] reported that a positive result for MRT decreased antibiotic use duration and prescription rate but the decrease in antibiotic prescription was not statistically significant. Timbrook et al. [15] studied MRT in combination with PCT and concluded that a lower level of PCT and detection of virus by MRT were not associated with decreased use of antibiotics in RTIs, but in another study, a lower level of PCT in combination with detection of virus was found to be associated with shortened duration of antibiotic usage [16]. In a randomized controlled study, the effect of both MRT and PCT on antibiotic use was evaluated and the duration of antibiotic use was found to be decreased in cases of viral infection with lower levels of PCT [17]. One of the strongest parts of our study was having the opportunity of ordering MRT whenever needed in routine clinical practice, so we reached a large sample size. We had the opportunity of getting the results of C-reactive protein, PCT, and MRT within a few hours, so we discriminated bacterial or viral etiology quickly. One of the limitations of this study was being conducted in a single center, but our center was unique for implementing this test in clinical practice. We are unique because MRT are still expensive to perform in routine clinical practice in other hospitals. Future studies for rapid point-of-care testing for respiratory viruses might improve clinical care by reducing unnecessary antibiotic use [18]. Future cost-effective studies for the implementation of MRT will be useful.

Conclusions

By using molecular rapid tests (MRT) in our hospital, inappropriate antibiotic use and also duration of inappropriate antibiotic use after the detection of virus was significantly decreased among inpatients. The treatment paradigm for respiratory tract infections (RTIs) is changing, but molecular viral diagnostic tests are in their infancy. It is time to increase the awareness of the viral etiology in RTIs and implement MRT in clinical practice.
  17 in total

1.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

2.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

3.  Clinical Diagnosis, Viral PCR, and Antibiotic Utilization in Community-Acquired Pneumonia.

Authors:  Zeeshan Afzal; Charles G Minard; Charles E Stager; Victor L Yu; Daniel M Musher
Journal:  Am J Ther       Date:  2016 May-Jun       Impact factor: 2.688

4.  Antibiotic use for viral acute respiratory tract infections remains common.

Authors:  Mark H Ebell; Taylor Radke
Journal:  Am J Manag Care       Date:  2015-10-01       Impact factor: 2.229

5.  Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.

Authors:  Katherine E Fleming-Dutra; Adam L Hersh; Daniel J Shapiro; Monina Bartoces; Eva A Enns; Thomas M File; Jonathan A Finkelstein; Jeffrey S Gerber; David Y Hyun; Jeffrey A Linder; Ruth Lynfield; David J Margolis; Larissa S May; Daniel Merenstein; Joshua P Metlay; Jason G Newland; Jay F Piccirillo; Rebecca M Roberts; Guillermo V Sanchez; Katie J Suda; Ann Thomas; Teri Moser Woo; Rachel M Zetts; Lauri A Hicks
Journal:  JAMA       Date:  2016-05-03       Impact factor: 56.272

6.  Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Marie R Griffin
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

7.  Antibiotic Discontinuation Rates Associated with Positive Respiratory Viral Panel and Low Procalcitonin Results in Proven or Suspected Respiratory Infections.

Authors:  Tristan Timbrook; Meshell Maxam; John Bosso
Journal:  Infect Dis Ther       Date:  2015-09-05

8.  Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial.

Authors:  Angela R Branche; Edward E Walsh; Roberto Vargas; Barbara Hulbert; Maria A Formica; Andrea Baran; Derick R Peterson; Ann R Falsey
Journal:  J Infect Dis       Date:  2015-04-24       Impact factor: 5.226

9.  The clinical impact of the detection of potential etiologic pathogens of community-acquired pneumonia.

Authors:  Gita Gelfer; James Leggett; Jillian Myers; Luan Wang; David N Gilbert
Journal:  Diagn Microbiol Infect Dis       Date:  2015-08-05       Impact factor: 2.803

10.  Evaluating the impact of the multiplex respiratory virus panel polymerase chain reaction test on the clinical management of suspected respiratory viral infections in adult patients in a hospital setting.

Authors:  Colin Yee; Eva Suarthana; Nandini Dendukuri; Ioana Nicolau; Makeda Semret; Charles Frenette
Journal:  Am J Infect Control       Date:  2016-06-13       Impact factor: 2.918

View more
  18 in total

1.  Rapid Molecular Detection of Gastrointestinal Pathogens and Its Role in Antimicrobial Stewardship.

Authors:  Şiran Keske; Burak Zabun; Kahraman Aksoy; Füsun Can; Erhan Palaoğlu; Önder Ergönül
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 2.  Syndromic Multiplex Polymerase Chain Reaction (mPCR) Testing and Antimicrobial Stewardship: Current Practice and Future Directions.

Authors:  Theodore S Rader; Michael P Stevens; Gonzalo Bearman
Journal:  Curr Infect Dis Rep       Date:  2021-02-26       Impact factor: 3.725

Review 3.  Antimicrobial Stewardship Interventions to Combat Antibiotic Resistance: an Update on Targeted Strategies.

Authors:  Kelli A Cole; Kaitlyn R Rivard; Lisa E Dumkow
Journal:  Curr Infect Dis Rep       Date:  2019-08-31       Impact factor: 3.663

4.  Opportunities Revealed for Antimicrobial Stewardship and Clinical Practice with Implementation of a Rapid Respiratory Multiplex Assay.

Authors:  Zoe F Weiss; Cheston B Cunha; Alison B Chambers; Audrey V Carr; Cleo Rochat; Mariska Raglow-Defranco; Diane M Parente; Aimee Angus; Leonard A Mermel; Latha Sivaprasad; Kimberle Chapin
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

5.  Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial.

Authors:  D Shengchen; X Gu; G Fan; R Sun; Y Wang; D Yu; H Li; F Zhou; Z Xiong; B Lu; G Zhu; B Cao
Journal:  Clin Microbiol Infect       Date:  2019-06-20       Impact factor: 8.067

6.  Low Uptake of Rapid Diagnostic Tests for Respiratory Tract Infections in an Urban Safety Net Hospital.

Authors:  Shana A B Burrowes; Alec Rader; Pengsheng Ni; Mari-Lynn Drainoni; Tamar F Barlam
Journal:  Open Forum Infect Dis       Date:  2020-03-03       Impact factor: 3.835

7.  More targeted use of oseltamivir and in-hospital isolation facilities after implementation of a multifaceted strategy including a rapid molecular diagnostic panel for respiratory viruses in immunocompromised adult patients.

Authors:  Laura M Vos; Jesper M Weehuizen; Andy I M Hoepelman; Karin H A H Kaasjager; Annelies Riezebos-Brilman; Jan Jelrik Oosterheert
Journal:  J Clin Virol       Date:  2019-04-07       Impact factor: 3.168

8.  A novel real-time PCR assay panel for detection of common respiratory pathogens in a convenient, strip-tube array format.

Authors:  Mohammad Rubayet Hasan; Hassan Al Mana; Virginia Young; Patrick Tang; Eva Thomas; Rusung Tan; Peter Tilley
Journal:  J Virol Methods       Date:  2018-12-19       Impact factor: 2.014

9.  Combining Procalcitonin and Rapid Multiplex Respiratory Virus Testing for Antibiotic Stewardship in Older Adult Patients With Severe Acute Respiratory Infection.

Authors:  Chien-Chang Lee; Julia Chia-Yu Chang; Xiao-Wei Mao; Wan-Ting Hsu; Shey-Ying Chen; Yee-Chun Chen; Chorng-Kuang How
Journal:  J Am Med Dir Assoc       Date:  2019-11-30       Impact factor: 4.669

10.  Rapid Molecular Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review of Diagnostic Accuracy and Clinical Impact Studies.

Authors:  Laura M Vos; Andrea H L Bruning; Johannes B Reitsma; Rob Schuurman; Annelies Riezebos-Brilman; Andy I M Hoepelman; Jan Jelrik Oosterheert
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.